GlassScriptPhysician profile
Taylor Bowman
NPI 1760903520
$1,104.60
in general payments reported to CMS, 2019-2025
13 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $35.97 · 2022: $138 · 2023: $234 · 2024: $354 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $392.71 | 2019-2025 | Rocklatan, Eysuvis, Simbrinza |
| Bausch & Lomb Americas INC. | $234.62 | 2024-2025 | Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $155.43 | 2022-2023 | |
| Glaukos Corporation | $120.97 | 2022-2024 | Photrexa, Ce-Marked Kxla System, Kxl1b-Ce-Marked Kxlsystem |
| Tarsus Pharmaceuticals, INC. | $51.63 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $28.08 | 2022-2024 | Tyrvaya, Ryzumvi |
| Astellas Pharma US INC | $23.06 | 2024 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sun Pharmaceutical Industries INC. | $18.83 | 2019 | |
| Dompe US, INC. | $18.73 | 2024 | Oxervate |
| Harrow Eye, LLC | $14.63 | 2024 | Vevye |
| Alcon Research LLC | $14.50 | 2019 | |
| Optos, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.